Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma
第一作者机构：[1]Beijing Tongren Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Liu Xin-di,Md Jia Cong,Yang Jing,et al.Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma[J].BLOOD.2024,144:6545-6545.doi:10.1182/blood-2024-203066.
APA：
Liu, Xin-di,Md, Jia Cong,Yang, Jing&Wang, Liang.(2024).Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma.BLOOD,144,
MLA：
Liu, Xin-di,et al."Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma".BLOOD 144.(2024):6545-6545
医学